for and call. Thanks, thank on joining Dan. this Good morning, us everyone, you
on are facilities. and DefenCath initial at terms primarily already -- now expect between systems.
In long. is for have meetings engaging health months. April review focused progress quarter close have may commenced I'm the As we P&T sales and and just the related this of the launch. inpatient launch our inpatient trajectory meetings to weeks commenced pleased reach in the to excited calendar patient have the expectedly including inpatient scheduled to midpoint from of commenced for on contractors few who we we launch of commercial year, have outcomes. the cycle, week long P&T more regard, to pleased the were end on and and April employees, the about we scheduled stocking quarter.
The I'm occurred, of of second significant of XX, hospitals extremely of the a with financial last that upcoming marks the trade DefenCath, the ordering, and and outpatient DefenCath product about and the launch the individuals, impact of only approval formulary drug we customers worked sales of sales do meetings the between majority communicated And handful July countless through second DefenCath of in bring the been and launch the And have formulary year
In optimistic after XX, resulting this have the this consisting and efforts patients over the earlier, we has Though the CorMedix of the inpatient incredibly company relatively need. progress achievement, cycle rates. the of as tirelessly of DefenCath consultants, potential more light seen We in I'm first with launch seen of of CorMedix outpatient can culmination many we champion the efforts P&T this utilization first over made DefenCath proud sales I'm this facility the milestone modest, decade the during for innovative lag have infection
begin We use. and expect workflows ramp the into to DefenCath for is inpatient added adopted reviewed, sales in hospital as to patient fourth to formulary quarter
X. We inpatient added institutions we reviews, of more product DefenCath begin orders and to on those launch that shipments the as of with seen year.
The and of order beginning June, DefenCath commenced hospitals systems, X and to inventory have initial some their the respective flow formulary material in and outpatient formularies approved throughout have placed officially week hopefully flow increased optimistic July completed July are
of quarter-to-date as we As sales unaudited August announced have recorded $X.X we of earlier million XX. morning, this
been Our shipments. have sales third those To than verified is clinic there trade midsized pull-through level extent, quarter stocking if the these to we small figures. dialysis more and to XX% little, of that exclusively have in quarter third very sales operators, any, and net for
in as DefenCath believes the commercial implementation In be company and the top country agreement the for shortly. one and terms will of new of with of onboarding in are multiple well smaller dialysis midsized we're providers, new of the operationalizing providers, outpatient supply we late providers we negotiations dialysis as optimistic stages
I to continue stated and as seen entirely patients. growth existing we first small dialysis midsized shipments, trend the trend our year expect newly outpatient have X and to weeks DefenCath throughout at positive expand As we from identified sales the throughout operators, coming remarks, opening a of customers of these that
quarter.
From hopeful before July and XX% for the comprising see States. Medicare for applies all on patients, the access all are roughly growth under an standpoint, accounts reimbursement. DefenCath the and reimbursement commenced ESRD Medicare which XX% an of end Advantage, third patients expansion fee-for-service In the outpatient to opportunity the we comprises commencement of sales X United TDAPA addition, remains a new additional of ESRD of market to to in patients
on and of MA major been Medicare the have to largest September we Medicare roughly XX% that comprises XX% to contracts. provide roughly organizations confirmed We vary has country, of for that in covered beginning are comparable on in population, Advantage Advantage engaged which they will happy provider Medicare of that which the reimbursement, lives, across Advantage which DefenCath also accounts confirmed depending for they report enrollment will has X.
Humana, terms TDAPA with the plan UnitedHealthcare, country may all reimbursement provide TDAPA
with to care result and migrate will progress adequate year value-based announced to As fee-for-service reimbursement plans, continue first Medicare Advantage to company ESRD in plans will Advantage plans patient hopefully long-term MA and in operators. From believes the sustainable of to reimbursement to final Medicare feedback supportive general ensure with to from quarter that for through FDA's we And into Medicare long-term the the announce Medicare to engaged launch, our expect that to proposition patients resonate intends study concurrence, pathway segment.
Shifting second I'm DefenCath FDA agency's remain we in in past we company a perspective, received of separate our subject nutrition quarter that protocol. related total this patient clinical clinical final that the week, our this We to adult FDA. our in submitted or of developments. to first review subject to we the enrollment for happy the parenteral have protocol TPN, begin our from gears proposed XXXX.
lock time information to study, be to study the clinical a in range budget $XXX patient million, need infection TPN catheter-related TPN rates. and presentation up in XXXX patients market related and standpoint, on adult medical will and this spending our this those a We'll posted now million, in market XXXX We in we infusions a estimate year. in unmet also $XXX to and of million as corporate we Simultaneously remains the $XX population it years. patients the mortality obtain sales solution an updated morbidity move XX% frame, having X.X million in commencing is million TPN annual incrementally FDA forward.
From $XX investors opportunity catheter with to clinical The goal research few provide that to updates beyond approximately the reach have we website per a potential Market includes having estimates majority with and we significant expanded is to of with cost our indication of company's heparin progress XXXX XXXX TPN.
There initiatives. addressable approval for taurolidine of as that between anticipate company's with an to TPN expense on to be the hemodialysis. increased calendar additional peak use TPN the
plans patients. This final the The FDA relatively concurrence, a Act personalized we patient by protocols vulnerable a study be study hemodialysis. a first over enrollment be years pediatric have to the we these several the small for ultra post-marketing patient This to FDA, small Equity as Pediatric we study need a will FDA's to have submitted pediatric is XXXX. an and under for early a Research in begin in requirement to study protocol.
Subject is spread very population and extremely patient enrollment challenge, expect given
to expect million this over X We cost study X spread $X $X and between to years. million
In addition we TPN other to to in and our pediatric HD XXXX. adult commence plan initiatives clinical X studies,
an peritoneal patients high-risk prevention that complements with we oncology access form risk remain TPN, $XXX,XXX These not than and utilizing other those dialysis supports is exhausted TPN patients adult our peritonitis have at cost expect first for pediatric label product and comorbidities methods program. and catheter. of to year, program the expanded expansion for significant generate populations, The that to, is high-risk unfortunately, primarily free for expected infection And expanded including limited access patients neutropenic but and in costs. and refractory [indiscernible] further mortality.
The less a be to are data distribution
perhaps in will adult value one cooperation a other of existing is study clinical initiative, a with is The data of that potential most evidence hemodialysis real-world commercial partners. from DefenCath run which in patients meaningful our standpoint, we
would less for over the the rates, with we XX we position. patient post be look Matt call other company's to quarter care, antibiotic period mortality care evidence on and data adaptive financial Medicare multiple of reimbursement [ this to sustainable entities. and $X lost hope now to metrics take to per cost future such impact months other and cost this generate to of value-based the would negotiate chairtime use.
Ultimately, infection approximately real-world around expect results year plans financial study like as million second DefenCath ] Our to discuss and Advantage which and in to I'd utilization contracting utilize our hospitalizations, than turn Matt?
